Epithelial ovarian cancer (EOC) is a chronic and degenerative disease propelled by mutation in BRCA1/2 genes, familial history, smoking and polycystic ovary syndrome. Although lifetime risk of ovarian cancer is low, yet it is the fifth leading cause of cancer related deaths. Surprisingly, EOC represents 90% of all ovarian cancers, out of which 70% women are diagnosed with the malignancy at its advanced III-IV stages. Early detection may increase the life expectancy up to 5 years. Thus, it has become need of the hour to attain improvement of clinical outcomes of EOC and improve life expectancy of patients. Plethora of proteins in different biological fluids may serve as prospective identifiers for the disease. Over the years, accurate identification of proteins secreted by EOC cells has been perfected by in vitro and in silico state of art technologies. Multivariate test, consisting of histo-pathological data in combination with protein biomarker panel has paved way for enhanced and accurate assessment for EOC, still there is a chance of further improvement. This review encompasses the inputs made in ovarian cancer biomarker discovery and demonstrates their potential usefulness for design of early diagnostics of EOC.

中文翻译：

---

上皮性卵巢癌预后中新兴的蛋白质生物标志物：多变量索引的辅助工具。

上皮性卵巢癌（EOC）是由BRCA1 / 2基因突变，家族史，吸烟和多囊卵巢综合症引起的慢性退行性疾病。尽管卵巢癌的终生风险较低，但它是与癌症相关的死亡的第五大主要原因。出乎意料的是，EOC占所有卵巢癌的90％，其中70％的女性被诊断出处于III-IV期晚期恶性肿瘤。尽早发现可将预期寿命延长至5年。因此，变得越来越需要提高EOC的临床疗效并提高患者的预期寿命。不同生物体液中的蛋白let可能会成为该疾病的前瞻性标识。这些年来，EOC细胞分泌的蛋白质的准确鉴定已通过体外和计算机技术水平的技术得以完善。由组织病理学数据与蛋白质生物标志物组合组成的多变量检验为增强和准确评估EOC铺平了道路，但仍有进一步改进的机会。这篇综述涵盖了在卵巢癌生物标志物发现中的投入，并证明了其对EOC早期诊断设计的潜在实用性。